Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker LXRX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obs… NCT06481891 · Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive H… Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Active, not recruiting | 500 | Jan 2027 | Registry ↗ |
| Feb 13, 2026 | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia NCT04662281 · Postherpetic Neuralgia Placebo, LX9211 | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 79 | Nov 18, 2022 | Registry ↗ |
| Oct 10, 2025 | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) NCT06203002 · Diabetic Peripheral Neuropathic Pain Placebo (blinded), LX9211 (blinded) | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 496 | Jan 14, 2025 | Registry ↗ |
| Jun 25, 2025 | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain NCT04455633 · Diabetic Peripheral Neuropathy, Diabetes LX9211, LX9211 Matching Placebo | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 319 | May 23, 2022 | Registry ↗ |
| Oct 28, 2022 | Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsenin… NCT03521934 · Heart Failure, Type 2 Diabetes Mellitus Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Terminated | 1,222 | Jun 5, 2020 | Registry ↗ |
| Oct 28, 2022 | Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and… NCT03315143 · Heart Failure, Type 2 Diabetes Mellitus Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Terminated | 10,584 | Jul 8, 2020 | Registry ↗ |
| Jun 25, 2021 | Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2… NCT03386344 · Type 2 Diabetes Mellitus Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Terminated | 376 | May 22, 2019 | Registry ↗ |
| Jun 25, 2021 | Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes,… NCT03242252 · Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3 Placebo, Sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 787 | Mar 25, 2019 | Registry ↗ |
| Jun 25, 2021 | A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Partic… NCT03242018 · Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4 Placebo, Sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 277 | May 16, 2019 | Registry ↗ |
| Jun 21, 2021 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not C… NCT02926937 · Type 2 Diabetes Mellitus Sotagliflozin (SAR439954), Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 399 | Apr 22, 2019 | Registry ↗ |
| May 11, 2021 | Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 D… NCT03351478 · Type 2 Diabetes Mellitus Sotagliflozin, Empagliflozin | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 770 | May 16, 2019 | Registry ↗ |
| May 11, 2021 | Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Dia… NCT03332771 · Type 2 Diabetes Mellitus Sotagliflozin (SAR439954), Glimepiride | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 954 | Aug 6, 2019 | Registry ↗ |
| May 11, 2021 | Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Partic… NCT03292653 · Cardiac Failure Aggravated Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 2 | Terminated | 32 | Aug 17, 2019 | Registry ↗ |
| May 11, 2021 | Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus W… NCT03285594 · Type 2 Diabetes Mellitus Sotagliflozin, Insulin glargine (HOE901) | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 571 | Sep 17, 2019 | Registry ↗ |
| May 11, 2021 | Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus o… NCT03066830 · Type 2 Diabetes Mellitus Sotagliflozin (SAR439954), Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 507 | Apr 17, 2019 | Registry ↗ |
| May 11, 2021 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Ba… NCT02926950 · Type 2 Diabetes Mellitus Sotagliflozin (SAR439954), Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 518 | Feb 26, 2019 | Registry ↗ |
| Feb 12, 2020 | A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have I… NCT02531035 · Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Gluco… Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 1,405 | Apr 2017 | Registry ↗ |
| Feb 12, 2020 | Dose-ranging Study in Patients With Type 1 Diabetes Mellitus NCT02459899 · Type 1 Diabetes Mellitus Placebo, Sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 141 | Aug 2016 | Registry ↗ |
| Feb 12, 2020 | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With… NCT02421510 · Type 1 Diabetes Mellitus Sotagliflozin, Sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 782 | Nov 2016 | Registry ↗ |
| Feb 12, 2020 | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With… NCT02384941 · Type 1 Diabetes Mellitus Placebo, Sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 793 | Sep 2016 | Registry ↗ |
| Feb 12, 2020 | Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elev… NCT02383940 · Type 1 Diabetes Mellitus Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 87 | Sep 2016 | Registry ↗ |
| Feb 12, 2020 | Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabe… NCT01742208 · Type 1 Diabetes Mellitus Sotagliflozin, Placebo | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 36 | Jan 2014 | Registry ↗ |
| Sep 17, 2019 | Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms NCT02026063 · Carcinoid Syndrome Telotristat etiprate | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 124 | Sep 12, 2018 | Registry ↗ |
| May 23, 2019 | A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute… NCT01456052 · Ulcerative Colitis Telotristat Etiprate, Placebo | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 59 | Sep 3, 2013 | Registry ↗ |
| Mar 15, 2019 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome NCT01104415 · Carcinoid Syndrome Telotristat etiprate | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 15 | Feb 12, 2014 | Registry ↗ |
| Feb 26, 2019 | Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function NCT02647918 · Renal Impairment, Healthy Sotagliflozin, Sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 50 | Sep 2017 | Registry ↗ |
| Dec 26, 2018 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Mana… NCT00853047 · Carcinoid Syndrome Telotristat etiprate, Octreotide LAR Depot | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 23 | Jun 2014 | Registry ↗ |
| Oct 15, 2018 | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairm… NCT03423446 · Hepatic Impairment Telotristat Ethyl | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 16 | Jun 15, 2018 | Registry ↗ |
| Apr 25, 2018 | A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotrist… NCT03302845 · Drug-drug Interaction Omeprazole 40 MG, Famotidine 40 mg | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 32 | Oct 23, 2017 | Registry ↗ |
| Feb 27, 2018 | TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndro… NCT01677910 · Carcinoid Syndrome Telotristat etiprate, Placebo-matching telotristat etiprate | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 135 | Mar 21, 2016 | Registry ↗ |
| Feb 26, 2018 | Telotristat Etiprate for Carcinoid Syndrome Therapy NCT02063659 · Carcinoid Syndrome Telotristat etiprate, Placebo | LXRX Lexicon Pharmaceuticals | Phase 3 | Completed | 76 | Mar 29, 2016 | Registry ↗ |
| Nov 17, 2016 | PK Study of Sotagliflozin in Subjects With Hepatic Impairment NCT02471274 · Hepatic Impairment, Healthy sotagliflozin | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 32 | Dec 2015 | Registry ↗ |
| Sep 7, 2016 | Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat… NCT02195635 · Drug Interactions Telotristat etiprate, Octreotide acetate | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 24 | Oct 2014 | Registry ↗ |
| Mar 2, 2016 | Oral Contraceptive DDI Study NCT02494609 · Healthy sotagliflozin, oral contraceptive | LXRX Lexicon Pharmaceuticals | Phase 1 | Unknown | 30 | Nov 2015 | Registry ↗ |
| Oct 2, 2015 | Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets NCT02373046 · Healthy LX4211, LX4211 | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 30 | Apr 2015 | Registry ↗ |
| Sep 14, 2015 | Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-an… NCT01528111 · Primary Open-angle Glaucoma, Ocular Hypertension LX7101 (0.125%), LX7101 (0.25%) | LXRX Lexicon Pharmaceuticals | Phase 1/2 | Completed | 63 | Jun 2012 | Registry ↗ |
| Jul 9, 2015 | DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin NCT02300363 · Healthy Treatment A (rosuvastatin), Treatment B (LX4211) | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 24 | Nov 2014 | Registry ↗ |
| Jul 9, 2015 | DDI Study With Multiple-dose LX4211 and Single Dose Digoxin NCT02300350 · Healthy Treatment A digoxin, Treatment B LX4211 | LXRX Lexicon Pharmaceuticals | Phase 1 | Completed | 24 | Dec 2014 | Registry ↗ |
| Mar 23, 2015 | A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predo… NCT01494233 · Irritable Bowel Syndrome 250 mg LX1033 tablets, Placebo tablet | LXRX Lexicon Pharmaceuticals | Phase 2 | Completed | 373 | Sep 2013 | Registry ↗ |
39 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:22 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances